Mechanisms of Action and Clinical Evidence for Treating Alzheimer’s Disease with Triple Wavelengths (660nm, 810nm, 1050nm)

Apr. 20, 2026

. Mechanisms of Action for Treating Alzheimer’s Disease with Triple Wavelengths

1. Core Principle: Photobiomodulation

Photobiomodulation (PBM) uses specific wavelengths of near-infrared and red light to non-invasively penetrate the skull and act on brain cell mitochondria, initiating a series of cellular repair and regeneration processes.

2. Specific Roles of Each Wavelength

Wavelength	Penetration Depth	Core Action Targeting Alzheimer‘s
660nm (Red Light)	2-8mm (Superficial Cortex)	Anti-inflammatory, promotes superficial circulation, protects neurons from oxidative stress
810nm (Near-Infrared)	3-5cm (Deep Cortex)	Activates mitochondrial CCO, increases ATP, reduces Aβ deposition, enhances synaptic plasticity
1050nm (Near-Infrared)	5-7cm (Hippocampus, Basal Ganglia)	Deepest penetration, reaches memory core regions (hippocampus), enhances energy metabolism

3. Five Major Therapeutic Mechanisms Targeting Alzheimer‘s Disease

Mechanism	Mode of Action	Clinical Significance
Mitochondrial Function Enhancement	Activates cytochrome c oxidase, increases ATP synthesis	Improves brain cell energy metabolism, delays neurodegeneration
Aβ Amyloid Protein Reduction	Upregulates Aβ-degrading enzymes, promotes microglial clearance of Aβ	2025 animal studies confirmed 55%-87% reduction in Aβ deposition
Anti-Neuroinflammation	Inhibits microglial activation, reduces pro-inflammatory cytokines (IL-6, TNF-α)	Reduces Alzheimer‘s-related neuroinflammation
Increased Cerebral Blood Flow	Vasodilation, promotes angiogenesis	Improves brain oxygen supply and nutrient delivery
Enhanced Synaptic Plasticity	Promotes BDNF release, enhances neural connections	Slows memory decline

II. Clinical Research Evidence

1. Animal Studies (2025)

Study	Parameters	Key Findings
APP/PS1 Mouse Model	810nm, 25 mW/cm², 20 min/day, 4 weeks	• 55%-87% reduction in Aβ deposition • 72% improvement in behavioral performance • Microglial transformation to anti-inflammatory phenotype

2. Mild Cognitive Impairment Clinical Study (2025)

Parameters	Results
Wavelength: 810nm (pulsed)	• MMSE cognitive score significantly improved (p=0.03)
Frequency: 40 Hz	• Episodic memory (CVLT-II) significantly improved (p=0.02)
Duration: 20 minutes/session	• Default mode network functional connectivity enhanced (p=0.014)
Frequency: 6 times/week	• Plasma IL-6 inflammatory factor decreased (p=0.02)
Course: 6 weeks	• Right thalamic volume increased

3. Alzheimer‘s Disease Clinical Trials (Ongoing)

Study Name	Treatment Protocol	Objective
TRAP-AD Study	808nm, 11 min/session, 3 times/week, 8 weeks	Evaluate cognitive improvement in AD patients
Transcranial PBM for AD	Multiple near-infrared wavelengths, transcranial irradiation of prefrontal cortex	Evaluate cognitive function and quality of life

Previous: None

Next: 904nm vs 980nm Lasers for Pain Relief

back to news